Journal: RSC Medicinal Chemistry
Article Title: Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation
doi: 10.1039/d6md00119j
Figure Lengend Snippet: Synthesis of VX-984: A) synthesis of intermediate 37; i) But-3-en-2-one, MeSO 3 H, AcOH, 90 °C; ii) NaOH (aq.); iii) SeO 2 , 1,4-dioxane, H 2 O, reflux, 30 min, 89%; iv) NaClO 2 , NaH 2 PO 4 , THF, H 2 O, 5 °C to rt, 2 h, 94%; v) (COCl) 2 , DMF, DCM, 10 °C; vi) MeNH 2 (aq.), THF, 5 °C to rt, 16 h, 90% (over 2 steps); vii) tert -butyl (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)carbamate, Pd(dppf)Cl 2 /DCM, Na 2 CO 3 , 1,4-dioxane, H 2 O, reflux, 16 h, 70%; viii) 5 M HCl in i PrOH, EtOH, 60 °C, 2 h; ix) Ac 2 O, NaHCO 3 , THF, H 2 O, 0 °C to rt, 12 h, 62% (over 2 steps); x) H 2 , 100 psi, Rh(COD)( R , R )-Et-DuPhos-OTf, MeOH, 50 °C, 14 h, 88%; xi) 6 M HCl, 60–70 °C, 4 days, 61%; xii) 4,6-dichloropyrimidine, Na 2 CO 3 , THF/H 2 O, 66 °C, 2 h, 88%; B) synethesis of intermediate 41: i) Pd (black), TEA, DCO 2 D, (D) 3 COD, 65%; ii) CuBr 2 , t BuNO 2 , MeCN, rt, 1 h, 49%; iii) B 2 pin 2 , PdCl 2 [P(cy) 3 ] 2 , KOAc, 2-MeTHF, 100 °C, (72% purity, carried forward); C) synthesis of VX-984; i) 2 M Na 2 CO 3 , Silacat DPP Pd, 1,4-dioxane, 90 °C, 16 h, 28%.
Article Snippet: VX-984 (M9831) is a selective inhibitor of DNA-PK cs , developed by Vertex Pharmaceuticals.
Techniques: Reflux